Creo Medical Group - MicroBlate™ Flex exceeds 100 clinical cases
Creo Medical Group plc
("Creo", the "Company" or the "Group")
MicroBlate™ Flex exceeds 100 clinical cases as adoption builds
Milestone reflects increasing utilisation across leading centres in the
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that more than 100 clinical cases have now been completed using its MicroBlate™ Flex microwave ablation product.
Exceeding 100 clinical cases marks an important step in building procedural expertise and clinical confidence. This milestone reflects the continuing progress in the clinical rollout of MicroBlate™ Flex following the previously announced commencement of lung tumour procedures. It also indicates increased use of a new breakthrough device changing lung cancer treatment as clinicians gain experience with the product and its integration into emerging minimally invasive treatment pathways. While the product is still at an early stage of roll-out the Company expects case numbers to rise rapidly over the next 12 months.
MicroBlate™ Flex is Creo's soft tissue microwave ablation product, designed to deliver precise, controlled ablation of nodules and tumours in several tissue types through a flexible endoscopic platform. MicroBlate™ Flex is particularly suited to the treatment of hard-to-reach lesions, including lung tumours, where minimally invasive access and precise energy delivery are critical. Management believe the potential market size for MicroBlate™ Flex applications is significant.
Alongside commercial development, Creo remains focused on expanding the clinical evidence base for MicroBlate™ Flex through ongoing clinical studies, post-market data generation, investigator-led research and scientific publications. Importantly, the growing body of clinical experience is contributing to the continued development of treatment workflows combining robotic-assisted navigation and flexible microwave ablation. This forms part of Creo's previously announced long-term collaboration with Intuitive Surgical, Inc. and is helping to build real-world experience in minimally invasive robotic-assisted lung tumour treatment pathways.
Commenting on the clinical experience, Professor
"The utility of robotic assisted bronchoscopy with Creo's MicroBlate™ Flex microwave ablation system broadens treatment options, particularly for patients with severe lung disease who may not have any other treatment options."
Commenting on the milestone,
"This milestone is a clear signal that the adoption and utilisation of MicroBlate™ Flex is building. We are seeing growing clinician engagement and utilisation, encouraging integration into clinical workflows across participating centres and real-world momentum as physicians gain experience with the product and its capabilities.
"The procedures in which MicroBlate™ Flex is being used have additional strategic value in helping clinicians develop treatment pathways that combine robotic navigation and microwave ablation, while also contributing to the evidence, workflow development and understanding of health economics that will support broader adoption.
"Together with our ongoing post-market clinical programme and previously announced long-term collaboration with Intuitive, this milestone is another important step in establishing MicroBlate™ Flex as a differentiated product in the evolving treatment landscape for early-stage lung cancer, where increasing rates of earlier diagnosis are creating greater demand for precise, minimally invasive options."
For further information please contact:
|
Creo Medical Group plc |
||
|
|
Via Walbrook PR |
|
|
|
|
|
|
Shore Capital (Nominated Adviser and Corporate Broker) |
+44 (0)20 7408 4090 |
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
|
|
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE